Pura Vida Investments, LLC Savara Inc Transaction History

Pura Vida Investments, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.05 - $1.36 $630 - $816	600 Added 0.64%	95,014 $124,000
Q4 2021 Feb 14, 2022	SELL	$1.04 - $1.34 $3,168 - $4,082	-3,047 Reduced 3.13%	94,414 $117,000
Q3 2021 Nov 15, 2021	SELL	$1.18 - $1.64 $2,344 - $3,258	-1,987 Reduced 2.0%	97,461 $134,000
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.29 $833 - $1,264	-552 Reduced 0.55%	99,448 $169,000
Q1 2021 May 12, 2021	BUY	$1.17 - $2.33 $117,000 - $233,000	100,000 New	100,000 $208,000
Q4 2020 Feb 16, 2021	SELL	$1.0 - $1.47 $266,570 - $391,857	-266,570 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.09 - $2.21 $89,595 - $181,657	-82,198 Reduced 23.57%	266,570 $291,000
Q2 2020 Aug 14, 2020	BUY	$1.8 - $3.05 $14,220 - $24,095	7,900 Added 2.32%	348,768 $868,000
Q1 2020 May 15, 2020	BUY	$1.91 - $4.08 $102,677 - $219,332	53,758 Added 18.72%	340,868 $723,000
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $203,848 - $1.41 Million	287,110 New	287,110 $1.29 Million
Q4 2017 Feb 14, 2018	SELL	$8.26 - $16.76 $1.43 Million - $2.9 Million	-173,023 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.1 - $9.55 $882,417 - $1.65 Million	173,023	173,023 $1.62 Billion

129

151M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $328M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Pura Vida Investments, LLC with notifications on news.